Progress and Challenges in "Getting to Zero" New HIV Infections in Miami, Florida

Overview

Journal J Int Assoc Provid AIDS Care

Publisher Sage Publications

Specialty Infectious Diseases

Date 2019 May 28

PMID 31131664

Citations 10

Authors

Daniel Javier Escudero

Brady Bennett

Sarah Suarez

William Ward Darrow

Kenneth Hugh Mayer

George Richard Seage 3rd

Affiliations

Soon will be listed here.

Abstract

Objectives: Miami has the highest rate of new HIV diagnoses in the United States. We examined the early successes and challenges in fulfilling recommendations made by the Miami-Dade County HIV/AIDS Getting to Zero Task Force, formed by local experts in 2016.

Methods: We used a host of surveillance data, published empirical studies, public reports, and unpublished data from partners of the Task Force to evaluate progress and challenges in meeting the recommendations.

Results: Improvements in prevention and care included routinized HIV testing in emergency departments, moving the linkage-to-care benchmark from 90 to 30 days, increased viral suppression, and awareness of pre-exposure prophylaxis. However, treatment enrollment, viral suppression, and pre-exposure prophylaxis uptake remained low.

Conclusions: Recommendations from the Task Force provide excellent guidance for implementing evidence-based HIV prevention in Miami, yet success in achieving the recommendations will require continued or increased support in many public health sectors in South Florida.

Citing Articles

COVID-19 vaccine implementation at a syringe services program: experiences of frontline staff.

Plesons M, Soto Sugar S, Chimbaru R, McDonald G, Friedman L, Thompson Jr E BMC Health Serv Res. 2024; 24(1):1260.

PMID: 39427164 PMC: 11490171. DOI: 10.1186/s12913-024-11691-9.

Barriers to Accessing and Engaging in HIV Preventive Care and Pre-Exposure Prophylaxis Experienced by Transgender Women in Florida.

Maragh-Bass A, Kiplagat S, Lavari S, Sastre F, Devieux J, Jimenez D Int J Environ Res Public Health. 2024; 21(3).

PMID: 38541377 PMC: 10970227. DOI: 10.3390/ijerph21030376.

Estimating the epidemiological impact of reaching the objectives of the Florida integrated HIV prevention and care plan in Miami-Dade County.

Zang X, Piske M, Humphrey L, Enns B, Sui Y, Marshall B Lancet Reg Health Am. 2023; 27:100623.

PMID: 37928440 PMC: 10624567. DOI: 10.1016/j.lana.2023.100623.

Stimulant use, HIV, and immune dysregulation among sexual minority men.

Cherenack E, Chavez J, Martinez C, Hirshfield S, Balise R, Horvath K Drug Alcohol Depend. 2023; 251:110942.

PMID: 37651812 PMC: 10544798. DOI: 10.1016/j.drugalcdep.2023.110942.

"The familiar taste of poison": a qualitative study of multi-level motivations for stimulant use in sexual minority men living in South Florida.

Davis-Ewart L, Lee J, Viamonte M, Colon-Burgos J, Harkness A, Kanamori M Harm Reduct J. 2023; 20(1):58.

PMID: 37101251 PMC: 10134657. DOI: 10.1186/s12954-023-00787-w.

References

Weller S, Davis K . Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev. 2002; (1):CD003255. DOI: 10.1002/14651858.CD003255. View

Padian N, McCoy S, Abdool Karim S, Hasen N, Kim J, Bartos M . HIV prevention transformed: the new prevention research agenda. Lancet. 2011; 378(9787):269-78. PMC: 3606928. DOI: 10.1016/S0140-6736(11)60877-5. View

Patrick R, Forrest D, Cardenas G, Opoku J, Magnus M, Phillips 2nd G . Awareness, Willingness, and Use of Pre-exposure Prophylaxis Among Men Who Have Sex With Men in Washington, DC and Miami-Dade County, FL: National HIV Behavioral Surveillance, 2011 and 2014. J Acquir Immune Defic Syndr. 2017; 75 Suppl 3:S375-S382. PMC: 5510477. DOI: 10.1097/QAI.0000000000001414. View

Spinner C, Boesecke C, Zink A, Jessen H, Stellbrink H, Rockstroh J . HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans. Infection. 2015; 44(2):151-8. DOI: 10.1007/s15010-015-0850-2. View

Stevens P, Galvao L . "He won't use condoms": HIV-infected women's struggles in primary relationships with serodiscordant partners. Am J Public Health. 2007; 97(6):1015-22. PMC: 1874207. DOI: 10.2105/AJPH.2005.075705. View

Cremin I, Alsallaq R, Dybul M, Piot P, Garnett G, Hallett T . The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis. AIDS. 2013; 27(3):447-58. DOI: 10.1097/QAD.0b013e32835ca2dd. View

Caceres C, Koechlin F, Goicochea P, Sow P, OReilly K, Mayer K . The promises and challenges of pre-exposure prophylaxis as part of the emerging paradigm of combination HIV prevention. J Int AIDS Soc. 2015; 18(4 Suppl 3):19949. PMC: 4509895. DOI: 10.7448/IAS.18.4.19949. View

Buttram M, Kurtz S . Preliminary evidence of HIV seroconversion among HIV-negative men who have sex with men taking non-prescribed antiretroviral medication for HIV prevention in Miami, Florida, USA. Sex Health. 2016; 14(2):193-195. DOI: 10.1071/SH16108. View

Wilson D . HIV treatment as prevention: natural experiments highlight limits of antiretroviral treatment as HIV prevention. PLoS Med. 2012; 9(7):e1001231. PMC: 3393678. DOI: 10.1371/journal.pmed.1001231. View

10.

Doblecki-Lewis S, Lester L, Schwartz B, Collins C, Johnson R, Kobetz E . HIV risk and awareness and interest in pre-exposure and post-exposure prophylaxis among sheltered women in Miami. Int J STD AIDS. 2015; 27(10):873-81. DOI: 10.1177/0956462415601304. View

11.

Marshall B, Paczkowski M, Seemann L, Tempalski B, Pouget E, Galea S . A complex systems approach to evaluate HIV prevention in metropolitan areas: preliminary implications for combination intervention strategies. PLoS One. 2012; 7(9):e44833. PMC: 3441492. DOI: 10.1371/journal.pone.0044833. View

12.

Garland P, Valverde E, Fagan J, Beer L, Sanders C, Hillman D . HIV counseling, testing and referral experiences of persons diagnosed with HIV who have never entered HIV medical care. AIDS Educ Prev. 2011; 23(3 Suppl):117-27. DOI: 10.1521/aeap.2011.23.3_supp.117. View

13.

Doblecki-Lewis S, Liu A, Feaster D, Cohen S, Cardenas G, Bacon O . Healthcare Access and PrEP Continuation in San Francisco and Miami After the US PrEP Demo Project. J Acquir Immune Defic Syndr. 2016; 74(5):531-538. PMC: 5340616. DOI: 10.1097/QAI.0000000000001236. View

14.

Koenig L, Lyles C, Smith D . Adherence to antiretroviral medications for HIV pre-exposure prophylaxis: lessons learned from trials and treatment studies. Am J Prev Med. 2012; 44(1 Suppl 2):S91-8. DOI: 10.1016/j.amepre.2012.09.047. View

15.

Hankins C, de Zalduondo B . Combination prevention: a deeper understanding of effective HIV prevention. AIDS. 2010; 24 Suppl 4:S70-80. DOI: 10.1097/01.aids.0000390709.04255.fd. View

16.

Dailey A, Hoots B, Hall H, Song R, Hayes D, Fulton Jr P . Vital Signs: Human Immunodeficiency Virus Testing and Diagnosis Delays - United States. MMWR Morb Mortal Wkly Rep. 2017; 66(47):1300-1306. PMC: 5708685. DOI: 10.15585/mmwr.mm6647e1. View

17.

Kirby T, Thornber-Dunwell M . Uptake of PrEP for HIV slow among MSM. Lancet. 2014; 383(9915):399-400. DOI: 10.1016/s0140-6736(14)60137-9. View

18.

Castel A, Feaster D, Tang W, Willis S, Jordan H, Villamizar K . Understanding HIV Care Provider Attitudes Regarding Intentions to Prescribe PrEP. J Acquir Immune Defic Syndr. 2015; 70(5):520-8. PMC: 4644475. DOI: 10.1097/QAI.0000000000000780. View

19.

Buttram M . The informal use of antiretroviral medications for HIV prevention by men who have sex with men in South Florida: initiation, use practices, medications and motivations. Cult Health Sex. 2018; 20(11):1185-1198. DOI: 10.1080/13691058.2017.1421709. View

20.

Kann L, McManus T, Harris W, Shanklin S, Flint K, Queen B . Youth Risk Behavior Surveillance - United States, 2017. MMWR Surveill Summ. 2018; 67(8):1-114. PMC: 6002027. DOI: 10.15585/mmwr.ss6708a1. View